Appl. No.

09/646,950

Filed

December 8, 2000

REMARKS

This is in response to a Notice to Comply mailed June 30, 2004. Therein, the Examiner

indicated that the Sequence Listing for the above-referenced patent application contained an error

in SEQ ID NO.:39. Additionally, the Examiner indicated that there were errors with regard to

spacing of various sequences.

Claims 8, 11, 13, 14, and 53 have been amended, Claims 22-37 have been cancelled

without prejudice, and new Claims 57-61 have been added. As a result, Claims 1-4, 8-20, 38-42,

and 52-61 remain pending in the present application. Support for the new claims is found in the

specification and claims as filed. Accordingly, the new claims do not constitute addition of new

matter.

Claims 8, 11, 13, 14, and 53 have been amended and new Claim 61 has been added so

that the claims conform to conventional practice before the United States Patent Office.

New Claims

New Claims 57-60 correspond to original Claims 5-7, and 21, respectively. In the

Amendment filed December 15, 2003, Applicant elected Group I, Claims 1-42 and 52-56.

Additionally, Applicant selected "treatment of autoimmune disease" as the single disclosed

species to which the claims are restricted should no generic claim is held to be allowable.

New Claims 57-60 are included in the elected invention, but are not readable on the

elected species. However, Claims 57-60 are dependent on a generic claim. Accordingly, upon

allowance of a generic claim be allowable, Claims 57-60 should also be allowable.

Replacement Sequence Listing

The Replacement Sequence Listing contains corrected SEQ ID NO:39. Additionally, the

spacing of all the sequences are proper, as indicated by the checking program. Enclosed herewith

are (1) a paper copy of the Replacement Sequence Listing and (2) a computer-readable version of

the Replacement Sequence Listing. This Response to Notice to Comply directs entry of the

-6-

Appl. No.

09/646,950

Filed

December 8, 2000

paper copy of the Listing into the application. In view of the foregoing, the application is believed to fully comply with the Sequence Listing disclosure requirements.

Verification under 37 C.F.R. § 1.821(f) & (g)

All of the sequences in the attached Replacement Sequence Listing were included in the application as filed. Pursuant to 37 C.F.R. § 1.821(g), no new matter is being added herewith. As required under 37 C.F.R. § 1.821(f), I hereby verify that the data on the enclosed disk and the paper copies of the Replacement Sequence Listing are identical.

Conclusion

Should there be any questions concerning this application, the Examiner is respectfully invited to contact the undersigned at the telephone number appearing below.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Registration No. 52,292

Agent of Record

Customer No. 20,995

(949) 760-0404

H:\DOCS\CCT\CCT-6289.DOC:cb

072604